tetano
Editor, Senior Moderator
Nat Med
. 2020 Jun 5.
doi: 10.1038/s41591-020-0949-6. Online ahead of print.
Seroprevalence of Immunoglobulin M and G Antibodies Against SARS-CoV-2 in China
Xin Xu[SUP] 1 2 [/SUP], Jian Sun[SUP] 1 2 [/SUP], Sheng Nie[SUP] 1 2 [/SUP], Huiyuan Li[SUP] 3 [/SUP], Yaozhong Kong[SUP] 4 [/SUP], Min Liang[SUP] 1 2 [/SUP], Jinlin Hou[SUP] 1 2 [/SUP], Xianzhong Huang[SUP] 3 [/SUP], Dongfeng Li[SUP] 5 [/SUP], Tean Ma[SUP] 6 [/SUP], Jiaqing Peng[SUP] 7 [/SUP], Shikui Gao[SUP] 8 [/SUP], Yong Shao[SUP] 9 [/SUP], Hong Zhu[SUP] 2 [/SUP], Johnson Yiu-Nam Lau[SUP] 10 [/SUP], Guangyu Wang[SUP] 11 [/SUP], Chunbao Xie[SUP] 12 [/SUP], Li Jiang[SUP] 12 [/SUP], Ailong Huang[SUP] 13 [/SUP], Zhenglin Yang[SUP] 14 [/SUP], Kang Zhang[SUP] 15 16 [/SUP], Fan Fan Hou[SUP] 17 18 19 [/SUP]
Affiliations
Abstract
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.
. 2020 Jun 5.
doi: 10.1038/s41591-020-0949-6. Online ahead of print.
Seroprevalence of Immunoglobulin M and G Antibodies Against SARS-CoV-2 in China
Xin Xu[SUP] 1 2 [/SUP], Jian Sun[SUP] 1 2 [/SUP], Sheng Nie[SUP] 1 2 [/SUP], Huiyuan Li[SUP] 3 [/SUP], Yaozhong Kong[SUP] 4 [/SUP], Min Liang[SUP] 1 2 [/SUP], Jinlin Hou[SUP] 1 2 [/SUP], Xianzhong Huang[SUP] 3 [/SUP], Dongfeng Li[SUP] 5 [/SUP], Tean Ma[SUP] 6 [/SUP], Jiaqing Peng[SUP] 7 [/SUP], Shikui Gao[SUP] 8 [/SUP], Yong Shao[SUP] 9 [/SUP], Hong Zhu[SUP] 2 [/SUP], Johnson Yiu-Nam Lau[SUP] 10 [/SUP], Guangyu Wang[SUP] 11 [/SUP], Chunbao Xie[SUP] 12 [/SUP], Li Jiang[SUP] 12 [/SUP], Ailong Huang[SUP] 13 [/SUP], Zhenglin Yang[SUP] 14 [/SUP], Kang Zhang[SUP] 15 16 [/SUP], Fan Fan Hou[SUP] 17 18 19 [/SUP]
Affiliations
- PMID: 32504052
- DOI: 10.1038/s41591-020-0949-6
Abstract
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.